Arbutus Biopharma’s (ABUS) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS) in a report issued on Tuesday,Benzinga reports. HC Wainwright currently has a $5.00 price objective on the biopharmaceutical company’s stock.

A number of other analysts also recently weighed in on the stock. JMP Securities increased their price target on shares of Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Chardan Capital reiterated a “buy” rating and issued a $5.00 target price (up from $4.50) on shares of Arbutus Biopharma in a report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Arbutus Biopharma has a consensus rating of “Moderate Buy” and an average target price of $5.50.

Arbutus Biopharma Trading Up 3.7 %

NASDAQ ABUS opened at $3.34 on Tuesday. Arbutus Biopharma has a 12 month low of $2.27 and a 12 month high of $4.72. The company has a market capitalization of $632.90 million, a PE ratio of -7.77 and a beta of 1.78. The stock has a 50-day simple moving average of $3.39 and a 200 day simple moving average of $3.72.

Hedge Funds Weigh In On Arbutus Biopharma

Institutional investors and hedge funds have recently modified their holdings of the business. Helen Stephens Group LLC bought a new position in Arbutus Biopharma in the third quarter valued at approximately $50,000. XTX Topco Ltd acquired a new stake in shares of Arbutus Biopharma during the second quarter worth $53,000. Ballentine Partners LLC acquired a new stake in shares of Arbutus Biopharma during the fourth quarter worth $102,000. China Universal Asset Management Co. Ltd. lifted its position in Arbutus Biopharma by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 36,309 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 14,138 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in Arbutus Biopharma in the 3rd quarter worth $142,000. 43.79% of the stock is currently owned by institutional investors and hedge funds.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.